A US Court of Appeals revived a challenge by Johnson & Johnson unit Auris Health Inc to a patent on a robotic tool used to perform surgery held by rival Intuitive Surgical Operations Inc.
The US Patent Trial and Appeal Board (PTAB) found that the two earlier patents included all the elements of Intuitive's. However, it said the patent was not obvious because a person of ordinary skill would not have been motivated to combine them because of skepticism at the time of the invention for using robotic systems during surgery in the first place.
A panel of the US Court of Appeals for the Federal Circuit Court ruled 2-1to direct the US Patent and Trademark Office's invention tribunal to revisit its determination that the 2012 patent, which covers a technique for more readily swapping out different surgical tools on a robotic surgical arm, was not obvious.
Auris petitioned the PTAB to invalidate Intuitive's patent in 2019, stating that it was obvious in light of two previous patents by other inventors. Those patents were for a robotic surgery interface and a robotic stand that could hold numerous instruments, respectively.
Robotic surgery uses robotic arms to manipulate surgical instruments under the supervision of a human surgeon. The technique is designed to provide surgeons with more precise control than traditional surgery.
The global robotic surgery market is expected to produce $5.46 billion in 2020, according to a report by Research and Markets. Auris is seen as a serious competitor to industry leader Intuitive.


Gold and Silver Prices Slide as Dollar Strength and Easing Tensions Weigh on Metals
Court Allows Expert Testimony Linking Johnson & Johnson Talc Products to Ovarian Cancer
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
India–U.S. Interim Trade Pact Cuts Auto Tariffs but Leaves Tesla Out
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Federal Judge Rules Trump Administration Unlawfully Halted EV Charger Funding
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
California Sues Trump Administration Over Federal Authority on Sable Offshore Pipelines
FDA Fast-Track Drug Reviews Delayed Over Safety and Efficacy Concerns
Minnesota Judge Rejects Bid to Halt Trump Immigration Enforcement in Minneapolis
TrumpRx.gov Highlights GLP-1 Drug Discounts but Offers Limited Savings for Most Americans
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 



